Early changes in PSA and association with outcomes in mCRPC patients.

Pasquale Rescigno,David Dolling,Mattia Rediti,Vincenza Conteduca,Michael Ong,Haoran Li,Aurelius Omlin,Sabine Schmid,Orazio Caffo,Andrea Zivi,Carmel Pezaro,Courtney Morley,Nuria Romero Laorden,maria isabel saez,Niven Mehra,Spyridon Sideris,Shahneen Sandhu,Cora N. Sternberg,Ugo De Giorgi,Johann S. de Bono

Early changes in PSA and association with outcomes in mCRPC patients.

2018

5063Background: Declines in prostate specific antigen (PSA) levels at 12-weeks are currently used to evaluate treatments response in metastatic castration resistant prostate cancer (mCRPC). Early P...

Keywords:

Physical therapy
Pathology
Medicine
Prostate-specific antigen
Prostate cancer
Oncology
Internal medicine
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations